Will molecular optical imaging have clinically important roles in stroke management, and how?

Journal of Clinical Neurology (Korea)

Volumn 6, Issue 1, 2010, Pages 10-18

  Lee, Dong Kun ^a   Nahrendorf, Matthias ^b   Schellingerhout, Dawid ^c   Kim, Dong Eog ^a  

^a Dongguk University Ilsan Hospital   (South Korea)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Molecular imaging; Optical imaging; Stroke

Indexed keywords

EID: 78651494256     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2010.6.1.10     Document Type: Review

References (88)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-486.
2. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006;37:1923-1932.
3. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
4. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
5. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004;13:125-138.
6. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient-Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 2006;98(2A):2H-15H.
7. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275.
8. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311-322.
9. Bang OY. Multimodal MRI for ischemic stroke: from acute therapy to preventive strategies. J Clin Neurol 2009;5:107-119.
10. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000;343:710-722.
11. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
12. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-2118.
13. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005;36:2311-2320.
14. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35(11 Suppl 1):2726-2730.
15. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006;12:1278-1285.
16. Rosell A, Foerch C, Murata Y, Lo EH. Mechanisms and markers for hemorrhagic transformation after stroke. Acta Neurochir Suppl 2008; 105:173-178.
17. Diedler J, Sykora M, Blatow M, Jüttler E, Unterberg A, Hacke W. Decompressive surgery for severe brain edema. J Intensive Care Med 2009;24:168-178.
18. Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, van Gijn J, van der Worp HB, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol 2009;8:326-333.
19. Köhrmann M, Schwab S. Hemicraniectomy for malignant middle cerebral artery infarction. Curr Opin Crit Care 2009;15:125-130.
20. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711.
21. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005;293:855-862.
22. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17:545-580.
23. Wickline SA, Lanza GM. Nanotechnology for molecular imaging and targeted therapy. Circulation 2003;107:1092-1095.
24. Fayad ZA. Cardiovascular molecular imaging. Arterioscler Thromb Vasc Biol 2009;29:981-982.
25. Tempany CM, McNeil BJ. Advances in biomedical imaging. JAMA 2001;285:562-567.
26. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219: 316-333.
27. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008;451:953-957.
28. Wong FC, Kim EE. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 2009;70:205-211.
29. Yang M, Jiang P, Hoffman RM. Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. Cancer Res 2007;67:5195-5200.
30. Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol 2009;29:983-991.
31. Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1017-1024.
32. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1009-1016.
33. Schwille P, Haupts U, Maiti S, Webb WW. Molecular dynamics in living cells observed by fluorescence correlation spectroscopy with one- and two-photon excitation. Biophys J 1999;77:2251-2265.
34. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-378.
35. Terai T, Nagano T. Fluorescent probes for bioimaging applications. Curr Opin Chem Biol 2008;12:515-521.
36. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 2005;23:313-320.
37. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123-128.
38. Chang K, Jaffer F. Advances in fluorescence imaging of the cardiovascular system. J Nucl Cardiol 2008;15:417-428.
39. Funovics MA, Weissleder R, Mahmood U. Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice. Radiology 2004;231:659-666.
40. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003;2:43-53.
41. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415-1425.
42. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-1282.
43. Crouse JR 3rd, Craven TE, Hagaman AP, Bond MG. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation 1995;92:1141-1147.
44. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002;15:439-446.
45. U-King-Im JM, Young V, Gillard JH. Carotid-artery imaging in the diagnosis and management of patients at risk of stroke. Lancet Neurol 2009;8:569-580.
46. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 2005; 36:2764-2772.
47. Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging 2002;15:62-67.
48. Lindner JR, Song J, Xu F, Klibanov AL, Singbartl K, Ley K, et al. Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes. Circulation 2000;102:2745-2750.
49. Weinberger J, Azhar S, Danisi F, Hayes R, Goldman M. A new noninvasive technique for imaging atherosclerotic plaque in the aortic arch of stroke patients by transcutaneous real-time B-mode ultrasonography: an initial report. Stroke 1998;29:673-676.
50. Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RK, Meldrum HE, et al. The causes and risk of stroke in patients with asymptomatic internal- carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 2000;342:1693-1700.
51. Lanzino G, Rabinstein AA, Brown RD Jr. Treatment of carotid artery stenosis: medical therapy, surgery, or stenting? Mayo Clin Proc 2009; 84:362-387; quiz 367-368.
52. Usman AA, Tang GL, Eskandari MK. Metaanalysis of procedural stroke and death among octogenarians: carotid stenting versus carotid endarterectomy. J Am Coll Surg 2009;208:1124-1131.
53. Rerkasem K, Rothwell PM. Temporal trends in the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis: an updated systematic review. Eur J Vasc Endovasc Surg 2009;37:504-511.
54. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47(8 Suppl):C13-C18.
55. Papaspyridonos M, Smith A, Burnand KG, Taylor P, Padayachee S, Suckling KE, et al. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006;26:1837-1844.
56. Lee S, Cha EJ, Park K, Lee SY, Hong JK, Sun IC, et al. A near-infrared- fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl 2008;47:2804-2807.
57. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation 2007;116:1052-1061.
58. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006;114:55-62.
59. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002;105:2766-2771.
60. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 2007;115: 377-386.
61. Kim DE, Kim JY, Schellingerhout D, Shon SM, Jeong SW, Kim EJ, et al. Molecular imaging of cathepsin B proteolytic enzyme activity reflects the inflammatory component of atherosclerotic pathology and can quantitatively demonstrate the antiatherosclerotic therapeutic effects of atorvastatin and glucosamine. Mol Imaging 2009;8:291-301.
62. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 2007;115: 2292-2298.
63. Sarai M, Hartung D, Petrov A, Zhou J, Narula N, Hofstra L, et al. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging. J Am Coll Cardiol 2007;50:2305-2312.
64. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004;350:1472-1473.
65. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003;108:2270-2274.
66. Trivedi RA, Mallawarachi C, U-King-Im JM, Graves MJ, Horsley J, Goddard MJ, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol c2006;26:1601-1606.
67. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008;117:379-387.
68. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007;13:636-641.
69. Kim DE, Tsuji K, Kim YR, Mueller FJ, Eom HS, Snyder EY, et al. Neural stem cell transplant survival in brains of mice: assessing the effect of immunity and ischemia by using real-time bioluminescent imaging. Radiology 2006;241:822-830.
70. Kim DE, Schellingerhout D, Jaffer FA, Weissleder R, Tung CH. Nearinfrared fluorescent imaging of cerebral thrombi and blood-brain barrier disruption in a mouse model of cerebral venous sinus thrombosis. J Cereb Blood Flow Metab 2005;25:226-233.
71. Jaffer FA, Tung CH, Wykrzykowska JJ, Ho NH, Houng AK, Reed GL, et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation 2004;110:170-176.
72. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999;94:271-305.
73. Robinson BR, Houng AK, Reed GL. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation 2000;102:1151-1157.
74. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99:3050-3055.
75. Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem 2004;11:2245-2260.
76. Woitzik J, Peña-Tapia PG, Schneider UC, Vajkoczy P, Thomé C. Cortical perfusion measurement by indocyanine-green videoangiography in patients undergoing hemicraniectomy for malignant stroke. Stroke 2006;37:1549-1551.
77. Coutinho JM, Majoie CB, Coert BA, Stam J. Decompressive hemicraniectomy in cerebral sinus thrombosis: consecutive case series and review of the literature. Stroke 2009;40:2233-2235.
78. Owens SL. Indocyanine green angiography. Br J Ophthalmol 1996; 80:263-266.
79. Czabanka M, Peña-Tapia P, Schubert GA, Woitzik J, Vajkoczy P, Schmiedek P. Characterization of cortical microvascularization in adult moyamoya disease. Stroke 2008;39:1703-1709.
80. Pestalozza IF, Di Legge S, Calabresi M, Lenzi GL. Ischaemic penumbra: highlights. Clin Exp Hypertens 2002;24:517-529.
81. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med 2008;14:497-500.
82. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
83. Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009;15:104-109.
84. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003; 63:8122-8125.
85. Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease- mediated photodynamic agent. Cancer Res 2006;66:7225-7229.
86. Kim DE, Kim JY, Schellingerhout D, Kim EJ, Kim HK, Lee S, et al. Protease Imaging of Human Atheromata Captures Molecular Information of Atherosclerosis, Complementing Anatomic Imaging. Arterioscler Thromb Vasc Biol 2010;30:449-456.
87. Kim DE, Jeong SW. Molecular Imaging of Atherosclerosis. J Korean Med Assoc 2009;52:143-150.
88. Kim DE, Kim JY, Kim EJ, Jeong SW. Molecular optical imaging of cathepsin-B proteolytic enzyme activity to reflect atherosclerosis pathophysiology and anti-atherosclerotic therapeutic effect. J Korean Neurol Assoc 2009;27:36-41.